title: Long-term treatment with transcutaneous estradiol and oral medroxyprogesterone acetate.
abstract: In an open prospective study with therapeutic monitoring, 34 women with climacteric symptoms, FSH > 40 IU/L and LH > 25 IU/L were treated for 12 months with an estradiol-depot-patch (Estraderm TTS) 50 micrograms twice a week and medroxyprogesterone acetate 10 mg tablets from 12th to 25th day of cycle. During the first months a significant improvement was seen in hot flushes and other climacteric inconveniences in terms of Kupperman's menopause index. During the study period FSH and LH were suppressed and the estrogen values were normalized. The fraction of free estradiol compared to protein bound estradiol remained unchanged during the whole treatment. The serum-lipids and serum-SHBG at inclusion were within normal limits and did not change during 12 months of treatment. Thus from these parameters no sign of any liver induction was seen. Ten patients had short term skin symptoms while four withdrew from the study because of persistent skin symptoms. Nine patients withdrew from the study, in five cases this was related to the therapy while in the other four it was due to other causes. Twenty-five (74%) women wished to continue the treatment after 12 months.
authors.affiliation: Department of Gynecology and Obstetrics, Svendborg Sygehus, Denmark.
authors.forename: O D
authors.initials: OD
authors.lastname: Pedersen
authors.forename: H K
authors.initials: HK
authors.lastname: Jensen
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D002979:Climacteric / Q000187:drug effects* / Q000378:metabolism; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D012738:Sex Hormone-Binding Globulin / Q000032:analysis
chemical_list: D003692:Delayed-Action Preparations; D008055:Lipids; D012738:Sex Hormone-Binding Globulin; D004970:Estrone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate